NCT02480439 is a Phase 1 clinical trial of TAK-648 Tablet in Healthy Volunteers, sponsored by Takeda.

Who is sponsoring NCT02480439?

NCT02480439 is sponsored by Takeda.

What drugs are being tested in NCT02480439?

Interventions in NCT02480439: TAK-648 Tablet, TAK-648 Oral Solution.

What condition does NCT02480439 study?

NCT02480439 studies Healthy Volunteers.

Is NCT02480439 still recruiting?

NCT02480439 is currently completed. Last updated 19 July 2016.

Are results published for NCT02480439?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-07-19 · How we verify

NCT02480439

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of a TAK-648 Tablet Compared With a TAK-648 Oral Solution, and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Completed Phase 1 Results posted Last updated 19 July 2016

What this trial tests

Phase 1 trial testing TAK-648 Tablet in Healthy Volunteers in 24 participants. Completed in 1 September 2015.

Timeline

1 June 2015

Primary endpoint
1 August 2015

1 September 2015

Quick facts

Lead sponsor	Takeda
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 June 2015
Primary completion	1 August 2015
Estimated completion	1 September 2015
Sites	1 location across United States

Drugs / interventions tested

TAK-648 Tablet — full drug profile →
TAK-648 Oral Solution

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Takeda — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cmax: Maximum Observed Plasma Concentration for TAK-648
Time frame: Day 1 pre-dose and multiple timepoints post-dose (Up to 72 hours) in each Period
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648
Time frame: Day 1 pre-dose and multiple timepoints post-dose (Up to 72 hours) in each Period
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648
Time frame: Day 1 pre-dose and multiple timepoints post-dose (Up to 72 hours) in each Period

Sponsor's own description

The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of Phosphodiesterase in the Biology and Pathology of Diabetes.
Kilanowska A, Ziółkowska A. · · 2020 · cited 20× · PMID 33153226 · DOI 10.3390/ijms21218244

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02480439 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 19 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02480439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing